On October 28, 2023, Forte Biosciences Inc announced that it has filed a motion to dismiss the Amended Complaint filed by Camac Partners LLC, stating that the Complaint alleges that Camac Partners have been and are engaged in a campaign of deceit and misinformation in an attempt to force the Company to liquidate for their benefit and to the detriment of the Company and other stockholders. In addition, the Company stated that it brings the claims against Camac and certain other Defendants for issuing false and misleading proxy statements in connection with their attempts to elect two members of Forte?s board at the Company?s 2023 annual meeting in violation of Section 14(a) of the Securities Exchange Act of 1934, and the Company also brings claims against Camac Partners under Exchange Act Section 13(d) for failure to file and for filing misleading Schedule 13Ds, including because Camac Partners failed to disclose that they were coordinating as a group. In addition, the Company stated that the Complaint seeks declarations that Camac Partners violated Sections 14(a) and 13(d) of the Exchange Act, an order directing Camac Partners to file true and correct proxy statements and Schedule 13Ds, an injunction prohibiting Camac Partners from issuing future materially misleading and false public filings, and money damages to compensate the Company for Camac Partners?

violations of law.